(Total Views: 1298)
Posted On: 05/16/2024 11:14:25 PM
Post# of 157709
12/7/22 CC
Cyrus
“18:50: Within oncology, we want to pursue colorectal cancer and breast cancer specifically.
Within the colorectal cancer population, we want to focus on a micro-satellite stable group, which represents about 85% of all diagnosed colorectal cancers. And within breast cancer, we want to focus on the hormone receptor positive HER2-negative population, which is about 70% of all diagnosed breast cancers, and the TNBC population since we have data in that space.”
The “urgent data” in CD07. Wonder what it will show us.
Cyrus
“18:50: Within oncology, we want to pursue colorectal cancer and breast cancer specifically.
Within the colorectal cancer population, we want to focus on a micro-satellite stable group, which represents about 85% of all diagnosed colorectal cancers. And within breast cancer, we want to focus on the hormone receptor positive HER2-negative population, which is about 70% of all diagnosed breast cancers, and the TNBC population since we have data in that space.”
The “urgent data” in CD07. Wonder what it will show us.
(13)
(0)
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
— Jeremiah 51:36
